Form 4: Royalty Pharma CEO Pablo Legorreta Reports Acquisition of 288,352 Class A Ordinary Shares
SEC Form 4 Filing
Pablo G. Legorreta, CEO and Chairman of the Board of Royalty Pharma plc, reported the acquisition of 288,352 Class A Ordinary Shares on May 8, 2025, alongside adjustments to his indirect beneficial ownership.
Summary
- On May 8, 2025, Pablo G. Legorreta, the CEO and Chairman of the Board of Royalty Pharma plc, reported a transaction involving Class A Ordinary Shares.
- He acquired 288,352 Class A Ordinary Shares at a price of $0 per share.
- This acquisition was exempt under Rule 16b-3 and related to the settlement of Equity Performance Awards.
- Following the transaction, Legorreta directly owns 352,147 Class A Ordinary Shares.
- He also has indirect ownership through various entities and trusts, including Legorreta Investments LLC, IRRA, SEP/IRA, Legorreta Children 2002 Trust, GST-Exempt Legorreta 2012 Family Trust, GST-Exempt Legorreta 2020 Family Trust, his spouse, Tata MC 35 Ltd., his son, his daughter, and Legorreta 2023 SR Trust.
- The total indirect ownership amounts to several million shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard SEC filing detailing an insider transaction. The acquisition of shares by the CEO could be seen as a positive sign, but it's part of a pre-existing compensation plan.
Positives
- The acquisition of shares by the CEO could be interpreted as a positive signal, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their ownership stakes.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, as it reflects the CEO's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 05/08/2025 | Date of the transaction: acquisition of Class A Ordinary Shares. |
| 05/09/2025 | Date of signature on the SEC Form 4 filing. |
Keywords
Royalty Pharma, Pablo Legorreta, Class A Ordinary Shares, Beneficial Ownership, SEC Form 4, Equity Performance Awards, Rule 16b-3, RPRX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.